Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALLERFED vs ADVIL ALLERGY AND CONGESTION RELIEF
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ALLERFED is a combination of an antihistamine (fexofenadine) and a decongestant (pseudoephedrine). Fexofenadine is a selective peripheral H1-receptor antagonist that blocks histamine effects, reducing allergy symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor activation, causing vasoconstriction of nasal mucosa.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which mediates inflammation, pain, and fever. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa, causing vasoconstriction.
Seasonal allergic rhinitis,Perennial allergic rhinitis,Nasal congestion associated with allergies
Temporary relief of symptoms due to hay fever or other upper respiratory allergies: nasal congestion, sinus pressure, sneezing, runny nose, itching of nose or throat, and itchy, watery eyes due to allergies.,Temporary reduction of fever.,Relief of minor aches and pains associated with the common cold, headache, toothache, muscular aches, backache, menstrual cramps, and arthritis pain.
1 tablet (pseudoephedrine 60 mg / triprolidine 2.5 mg) orally every 4-6 hours; not to exceed 4 doses per 24 hours.
Ibuprofen 200 mg and pseudoephedrine HCl 30 mg per tablet. Usual adult dose: 1-2 tablets orally every 4-6 hours as needed, not to exceed 6 tablets in 24 hours.
Terminal elimination half-life 20-24 hours; clinically significant for once-daily dosing in seasonal allergic rhinitis.
Ibuprofen: 2-4 hours; pseudoephedrine: 5-8 hours. Shorter half-life requires frequent dosing for sustained relief.
Fexofenadine is minimally metabolized (<5%) in the liver; primarily excreted unchanged in feces (80%) and urine (11%). Pseudoephedrine is partially metabolized in the liver by N-demethylation and excreted mostly unchanged in urine.
Ibuprofen is primarily metabolized by cytochrome P450 (CYP) enzymes, mainly CYP2C9, to inactive metabolites (hydroxyibuprofen and carboxyibuprofen). Pseudoephedrine is partially metabolized in the liver by N-demethylation to an inactive metabolite.
Primarily renal (approximately 60-70% as unchanged drug and metabolites); minor biliary (10-15%); fecal (5-10%).
Renal excretion of unchanged drug and metabolites; approximately 1% excreted unchanged (pseudoephedrine) and 15% (ibuprofen). Biliary/fecal elimination accounts for <5%.
80-85% bound to albumin and alpha-1-acid glycoprotein.
Ibuprofen: 99% bound to albumin; pseudoephedrine: negligible protein binding.
Vd 5-7 L/kg, indicating extensive tissue distribution beyond plasma volume.
Ibuprofen: 0.1-0.2 L/kg; pseudoephedrine: 2.5-3 L/kg.
Oral: 40-50% due to first-pass metabolism; intranasal: 70-80%.
Oral: ibuprofen 80-100%; pseudoephedrine 100%.
Cr Cl 30-50 m L/min: administer every 6-8 hours. Cr Cl 10-29 m L/min: administer every 8-12 hours. Cr Cl <10 m L/min: not recommended.
For pseudoephedrine: Cr Cl <30 m L/min, reduce dose by 50% or administer every 12 hours. For ibuprofen: avoid use if Cr Cl <30 m L/min; if Cr Cl 30-59 m L/min, use lowest effective dose and monitor renal function.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% or extend interval. Child-Pugh Class C: avoid use.
For ibuprofen: Child-Pugh class A and B: no adjustment necessary; Child-Pugh class C: avoid use. For pseudoephedrine: use with caution in severe hepatic impairment; no specific dose adjustment recommended, but monitor for adverse effects.
Children 6-12 years: 1/2 tablet (pseudoephedrine 30 mg / triprolidine 1.25 mg) orally every 4-6 hours; max 2 doses per 24 hours. Children <6 years: not recommended.
Not indicated for children under 12 years of age. For children 12 years and older: same as adult dose (1-2 tablets every 4-6 hours, max 6 tablets per day). Weight-based: not routinely used; safety and efficacy not established for <25 kg.
Initiate at half the adult dose; monitor for anticholinergic effects, dizziness, and hypertension; maximum 2 doses per 24 hours.
For ibuprofen: use lowest effective dose for shortest duration; monitor renal function and GI bleeding risk. For pseudoephedrine: initiate at lower doses (e.g., one tablet every 6 hours) due to increased sensitivity and risk of hypertension, urinary retention, and CNS effects.
None.
Cardiovascular risk: NSAIDs may increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. Contraindicated for perioperative pain in coronary artery bypass graft (CABG) surgery. Gastrointestinal risk: NSAIDs increase the risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Elderly patients and those with prior peptic ulcer disease and/or GI bleeding are at greater risk.
Severe hypertension,Coronary artery disease,Ischemic heart disease,Increased intraocular pressure,Diabetes,Thyroid disease,Prostatic hypertrophy,Renal impairment,Use with caution in elderly,Avoid with MAOIs or within 14 days of stopping
Cardiovascular effects: may increase risk of heart attack or stroke; use lowest effective dose for shortest duration. Gastrointestinal effects: may cause GI ulceration, bleeding, perforation. Renal effects: avoid in advanced renal disease; monitor renal function. Hepatic effects: may cause liver enzyme elevation; discontinue if liver disease develops. Anaphylactic reactions: may occur in patients with or without prior NSAID sensitivity. Asthma: may cause bronchospasm. Hypertension: may worsen hypertension. Avoid in late pregnancy due to risk of premature closure of ductus arteriosus. Pseudoephedrine: may cause nervousness, dizziness, insomnia, hypertension, arrhythmias; use with caution in patients with cardiovascular disease, diabetes, glaucoma, prostatic hypertrophy, hyperthyroidism. Avoid in severe hypertension or coronary artery disease.
Hypersensitivity to any component,Severe hypertension,Severe coronary artery disease,Use with or within 14 days of MAOIs,Narrow-angle glaucoma,Urinary retention,Severe renal impairment (Cr Cl <30 m L/min)
Hypersensitivity to ibuprofen, pseudoephedrine, or any component of the formulation. History of asthma, urticaria, or allergic-type reaction after taking aspirin or other NSAIDs. In the setting of coronary artery bypass graft (CABG) surgery. Severe hypertension. Coronary artery disease. Concurrent use with or within 14 days of monoamine oxidase inhibitors (MAOIs) due to risk of hypertensive crisis. Pregnancy (third trimester).
Avoid high-tyramine foods (e.g., aged cheeses, cured meats, fermented foods) if taking MAOIs concurrently. Grapefruit juice may increase absorption of triprolidine. Caffeine may enhance stimulant effects of pseudoephedrine.
Take with food or milk to minimize GI upset. Avoid alcohol as it may increase risk of GI bleeding. No specific food-drug interactions.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies suggest possible increased risk of minor malformations. Second/third trimester: Use associated with reduced uterine blood flow and fetal tachycardia; avoid near term due to risk of prolonged QT interval in neonate.
First trimester: Possible increased risk of cardiovascular malformations and gastroschisis with NSAID use. Second trimester: No specific malformation risk reported, but avoid prolonged use due to potential oligohydramnios. Third trimester: NSAIDs (including ibuprofen) are contraindicated due to risk of premature ductus arteriosus closure and oligohydramnios. Pseudoephedrine: Limited data; possible association with gastroschisis if used in first trimester; avoid due to vasoconstrictive effects.
Excreted in breast milk with M/P ratio of approximately 0.5. American Academy of Pediatrics considers compatible with breastfeeding; however, use with caution due to potential for irritability and drowsiness in infant.
Ibuprofen: Excreted in low levels (M/P ratio ~0.006); considered compatible with breastfeeding. Pseudoephedrine: Excreted in breast milk (M/P ratio ~2.5-3.5); may reduce milk production and cause irritability in infants; use with caution.
Increased plasma volume and renal clearance in pregnancy may reduce drug concentrations; however, specific dose adjustment is not routinely recommended due to limited data. Use lowest effective dose for shortest duration.
Ibuprofen: No specific dose adjustment recommended for pregnancy; however, avoid use in third trimester. Pseudoephedrine: No dose adjustment studied; use lowest effective dose for shortest duration. Neither drug is recommended for regular use during pregnancy.
Allerfed combines pseudoephedrine and triprolidine. Use with caution in hypertension, cardiovascular disease, and glaucoma. Avoid in patients with severe hypertension or coronary artery disease. Limit duration to 5-7 days to avoid rebound congestion. Anticholinergic effects may cause urinary retention in BPH.
Combination of ibuprofen (NSAID) and pseudoephedrine (decongestant). Ibuprofen may increase blood pressure, counteracting pseudoephedrine's vasoconstriction; monitor in hypertensive patients. Avoid in patients with severe CAD, uncontrolled HTN, or within 2 weeks of MAOI use.
Take with food or milk to reduce stomach upset.,Do not exceed recommended dose; avoid taking more than every 4-6 hours.,Avoid alcohol while taking this medication.,If symptoms persist for more than 7 days, consult your doctor.,May cause drowsiness; avoid driving or operating heavy machinery until you know how you react.
Do not take with other NSAIDs or cold/flu products to avoid overdose.,Pseudoephedrine may cause insomnia; take last dose at least 4-6 hours before bedtime.,Ibuprofen can cause GI bleeding; take with food or milk to reduce risk.,Stop use and consult doctor if symptoms persist >7 days or if fever lasts >3 days.,Avoid alcohol while taking this medication.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALLERFED vs ADVIL ALLERGY AND CONGESTION RELIEF, answered by our medical review team.
ALLERFED is a Decongestant that works by ALLERFED is a combination of an antihistamine (fexofenadine) and a decongestant (pseudoephedrine). Fexofenadine is a selective peripheral H1-receptor antagonist that blocks histamine effects, reducing allergy symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor activation, causing vasoconstriction of nasal mucosa.. ADVIL ALLERGY AND CONGESTION RELIEF is a NSAID/Decongestant Combination that works by Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which mediates inflammation, pain, and fever. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa, causing vasoconstriction.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALLERFED and ADVIL ALLERGY AND CONGESTION RELIEF depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALLERFED is: 1 tablet (pseudoephedrine 60 mg / triprolidine 2.5 mg) orally every 4-6 hours; not to exceed 4 doses per 24 hours.. The standard adult dose of ADVIL ALLERGY AND CONGESTION RELIEF is: Ibuprofen 200 mg and pseudoephedrine HCl 30 mg per tablet. Usual adult dose: 1-2 tablets orally every 4-6 hours as needed, not to exceed 6 tablets in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALLERFED and ADVIL ALLERGY AND CONGESTION RELIEF in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALLERFED is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data; animal studies suggest possible increased risk of minor malformations. Second/third trimester: Use associated with re. ADVIL ALLERGY AND CONGESTION RELIEF is classified as Category C. First trimester: Possible increased risk of cardiovascular malformations and gastroschisis with NSAID use. Second trimester: No specific malformation risk reported, but avoid prolo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.